Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma

argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly.

Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to its preclinical candidate, ARGX-112, though an amount has not been disclosed.

The antibody, indicated for inflammatory skin diseases, was discovered with the biotech’s SIMPLE discovery platform. The Belgian biotech will carry out preclinical R&D on ARGX-112; once it hits the clinic, Leo will take over. Under the terms of the deal, the pharma holds the option to exclusive global licensing.


Image via Copula / shutterstock.com

Previous post

"We're at a second revolution in cancer therapy" - Experts discuss the Future of Oncology at Refresh

Next post

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.